A Legacy of Courage and Innovation
Professor Richard Scolyer, a distinguished pathologist and joint Australian of the Year (2024), passed away at the age of 59. His journey, marked by extraordinary courage and scientific contribution, left an indelible mark on the world of medicine.
Scolyer captured global attention when he volunteered to undergo a groundbreaking experimental treatment for brain cancer. This decision not only extended his life but also provided invaluable insights that will shape the future of brain cancer therapy. In an open letter intended for publication after his passing, he expressed:
“I sincerely hope the scientific data and awareness I have generated will provide a platform for others to build upon to ultimately make a difference for future cancer patients.”
Richard Scolyer is survived by his wife, Dr Katie Nicoll, and their three children, Emily, Matt, and Lucy.
Finding His Calling
Born in the suburb of Riverside in Launceston, Tasmania, Scolyer described his childhood as largely happy, filled with typical activities such as biking and playing football. His family enjoyed annual beach holidays, spending time swimming and playing cricket.
A lifelong sportsman, Scolyer excelled in football during his youth, later taking up swimming, cycling, and running. He often used these passions to raise funds for charity. By year ten, he had already decided on a career in medicine, a path he pursued successfully at The University of Tasmania.
Once qualified, Scolyer became renowned for his compassion and dedication to his patients. His specialty was melanoma, and he was regarded as one of the finest melanoma pathologists globally. In 2017, he was appointed Co-Medical Director of the Melanoma Institute of Australia alongside Professor Georgina Long, his friend and fellow 2024 Australian of the Year recipient.
Battling Glioblastoma
In mid-2023, Scolyer was diagnosed with advanced (stage 4) glioblastoma, the most aggressive and common form of brain cancer. Survival rates for this disease are typically around one year, with treatment methods remaining largely unchanged over nearly two decades. These treatments usually involve chemotherapy, radiation therapy, and surgery, yet the cancer often returns.
Faced with a grim prognosis, Scolyer chose to participate in a new treatment approach inspired by immunotherapies used in melanoma research. These therapies aim to harness the power of the immune system to fight cancer.
Trailblazing Cancer Therapy
Immunotherapy is a rapidly evolving field of medicine. The immune system is incredibly powerful, capable of eliminating almost anything—even itself. Severe allergic reactions, for example, occur when the immune system mistakenly attacks the body, sometimes with lethal consequences.
To keep the immune system in check, the body uses “checkpoints” — proteins on immune cells that act like an “off switch.” One of the most widely used immunotherapies involves “immune checkpoint inhibitors,” which “turn off the off switch,” allowing the immune system to attack cancer cells more effectively.
Scolyer received simultaneous doses of three different checkpoint inhibitors, followed by surgery to remove as much cancer as possible from his brain 12 days later. He then underwent six weeks of radiation therapy, additional checkpoint inhibitors, and even a personalized peptide vaccination.
Peptide vaccination is another form of immunotherapy. It aims to teach the immune system to recognize a patient’s cancer cells so it can better combat them if they return. Eighteen months after surgery, Scolyer’s tumor was still gone — an incredible achievement for a disease as difficult to treat as glioblastoma.
This success led to the creation of a clinical trial exploring how this new treatment can be adapted for broader use in the future. Scolyer’s bravery and innovative approach will likely extend the lives of hundreds, if not thousands, of people diagnosed with glioblastoma in the years to come.
A Remarkable Extension
In March 2025, Scolyer announced that his cancer had returned. This came almost two years after his original diagnosis — a remarkable extension of his life given the severity of his condition.
Though his battle has ended, Scolyer’s legacy will live on through the memories of those who knew him and the countless lives he has touched through his contributions to science and medicine. His work will continue to benefit patients worldwide, even if they never knew his name.
